BiotechTube

Control group (standard hospital treatment) + Group Hydroxychloroquine + Group Hydroxychloroquine and apixaban + Group Apixaban

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complication

Conditions

Complication

Trial Timeline

Jul 1, 2020 → Dec 23, 2020

NCT ID
NCT04788355

About Control group (standard hospital treatment) + Group Hydroxychloroquine + Group Hydroxychloroquine and apixaban + Group Apixaban

Control group (standard hospital treatment) + Group Hydroxychloroquine + Group Hydroxychloroquine and apixaban + Group Apixaban is a phase 3 stage product being developed by Pfizer for Complication. The current trial status is completed. This product is registered under clinical trial identifier NCT04788355. Target conditions include Complication.

What happened to similar drugs?

13 of 16 similar drugs in Complication were approved

Approved (13) Terminated (2) Active (2)
✅Fospropofol + Propofol/LidocaineEisaiApproved
✅Metformin + PlaceboEli LillyApproved
✅LOKELMA 5 GM Powder for Oral Suspension + PlacebosAstraZenecaApproved
✅Sugammadex + Neostigmine/GlycopyrrolateMerckApproved
✅Quadravalent human papillomavirus vaccineMerckApproved
✅Sugammadex + NeostigmineMerckApproved
✅Sugammadex 100 MG/ML [Bridion]MerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04788355Phase 3Completed

Competing Products

20 competing products in Complication

See all competitors
ProductCompanyStageHype Score
Fospropofol + Propofol/LidocaineEisaiApproved
43
exenatideEli LillyPhase 2
27
Metformin + PlaceboEli LillyApproved
43
LOKELMA 5 GM Powder for Oral Suspension + PlacebosAstraZenecaApproved
39
deep neuromuscular blockMerckPre-clinical
26
Sugammadex + Neostigmine/GlycopyrrolateMerckApproved
35
Quadravalent human papillomavirus vaccineMerckApproved
43
Sugammadex + NeostigmineMerckApproved
43
Sugammadex 100 MG/ML [Bridion]MerckApproved
43
Letermovir 480 mg once dailyMerckPhase 3
44
RocuroniumMerckPre-clinical
26
Everolimus + Tacrolimus + Mycophenolic acidNovartisApproved
39
Ranibizumab + 0.9% Sodium ChlorideNovartisPhase 2/3
38
Aztreonam Lysine for Inhalation (AZLI)Gilead SciencesApproved
43
Liraglutide + PlaceboNovo NordiskApproved
43
Semaglutide Treatment + Sitagliptin 100mgNovo NordiskApproved
39
DonepezilPfizerApproved
43
sodium thiosulfateSanofiPre-clinical
26
Finerenone Oral Tablet + PlaceboBayerPhase 2
39
LA-EP2006 + Neulasta®Sandoz GroupPhase 3
37